4.5 Review

Fourier-transform ion cyclotron resonance mass spectrometry for characterizing proteoforms

Journal

MASS SPECTROMETRY REVIEWS
Volume 41, Issue 2, Pages 158-177

Publisher

WILEY
DOI: 10.1002/mas.21653

Keywords

heart disease; post-translational modifications; proteoform; top-down MS; middle-down MS

Categories

Funding

  1. NIH R01 grants [GM117058, GM125085, HL109810, HL096971]
  2. NIH Chemistry and Biology Interface Training Program [T32 GM008505]
  3. high-end instrument grant [S10 OD018475]

Ask authors/readers for more resources

In this article, the application of Fourier-transform ion cyclotron resonance mass spectrometry (FT-ICR MS) in the study of proteoforms is reviewed. The unique features of FT-ICR MS in measuring proteoform mass with ultrahigh resolution and accuracy, obtaining comprehensive proteoform sequence coverage, and identifying modifications are highlighted. The importance of quantifying and characterizing proteoforms in biological systems such as the heart and skeletal muscle is emphasized, along with the use of FT-ICR MS in monoclonal antibody and proteomics studies. It is predicted that FT-ICR MS will continue to advance the study of complex proteoforms and play a key role in clinical diagnostics.
Proteoforms contribute functional diversity to the proteome and aberrant proteoforms levels have been implicated in biological dysfunction and disease. Fourier-transform ion cyclotron resonance mass spectrometry (FT-ICR MS), with its ultrahigh mass-resolving power, mass accuracy, and versatile tandem MS capabilities, has empowered top-down, middle-down, and native MS-based approaches for characterizing proteoforms and their complexes in biological systems. Herein, we review the features which make FT-ICR MS uniquely suited for measuring proteoform mass with ultrahigh resolution and mass accuracy; obtaining in-depth proteoform sequence coverage with expansive tandem MS capabilities; and unambiguously identifying and localizing post-translational and noncovalent modifications. We highlight examples from our body of work in which we have quantified and comprehensively characterized proteoforms from cardiac and skeletal muscle to better understand conditions such as chronic heart failure, acute myocardial infarction, and sarcopenia. Structural characterization of monoclonal antibodies and their proteoforms by FT-ICR MS and emerging applications, such as native top-down FT-ICR MS and high-throughput top-down FT-ICR MS-based proteomics at 21 T, are also covered. Historically, the information gleaned from FT-ICR MS analyses have helped provide biological insights. We predict FT-ICR MS will continue to enable the study of proteoforms of increasing size from increasingly complex endogenous mixtures and facilitate the benchmarking of sensitive and specific assays for clinical diagnostics. (c) 2020 John Wiley & Sons Ltd. Mass Spec Rev

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available